LT3788043T - Nikotino acetilcholino receptorių alosteriniai spiropiperidino moduliatoriai - Google Patents

Nikotino acetilcholino receptorių alosteriniai spiropiperidino moduliatoriai

Info

Publication number
LT3788043T
LT3788043T LTEPPCT/US2019/029561T LTUS2019029561T LT3788043T LT 3788043 T LT3788043 T LT 3788043T LT US2019029561 T LTUS2019029561 T LT US2019029561T LT 3788043 T LT3788043 T LT 3788043T
Authority
LT
Lithuania
Prior art keywords
spiropiperidine
allosteric
modulators
acetylcholine receptors
nicotine acetylcholine
Prior art date
Application number
LTEPPCT/US2019/029561T
Other languages
English (en)
Inventor
Brendan CROWLEY
Brian Campbell
Harry Chobanian
James Fells
Deodial Guiadeen
Thomas Greshock
Kenneth LEAVITT
Vanessa RADA
Ian Bell
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of LT3788043T publication Critical patent/LT3788043T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2019/029561T 2018-05-01 2019-04-29 Nikotino acetilcholino receptorių alosteriniai spiropiperidino moduliatoriai LT3788043T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862665091P 2018-05-01 2018-05-01
PCT/US2019/029561 WO2019212927A1 (en) 2018-05-01 2019-04-29 Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Publications (1)

Publication Number Publication Date
LT3788043T true LT3788043T (lt) 2024-12-27

Family

ID=66429709

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2019/029561T LT3788043T (lt) 2018-05-01 2019-04-29 Nikotino acetilcholino receptorių alosteriniai spiropiperidino moduliatoriai

Country Status (39)

Country Link
US (1) US11332463B2 (lt)
EP (1) EP3788043B1 (lt)
JP (1) JP7073533B2 (lt)
KR (1) KR102587811B1 (lt)
CN (1) CN112119076B (lt)
AR (1) AR115065A1 (lt)
AU (1) AU2019262917B2 (lt)
BR (1) BR112020022088A8 (lt)
CA (1) CA3098583C (lt)
CL (2) CL2020002820A1 (lt)
CO (1) CO2020013462A2 (lt)
CR (1) CR20200509A (lt)
DK (1) DK3788043T3 (lt)
EA (1) EA202092608A1 (lt)
EC (1) ECSP20067907A (lt)
ES (1) ES2995040T3 (lt)
FI (1) FI3788043T3 (lt)
GE (2) GEP20227409B (lt)
HR (1) HRP20241704T1 (lt)
HU (1) HUE070339T2 (lt)
IL (1) IL278154B2 (lt)
JO (1) JOP20200272A1 (lt)
LT (1) LT3788043T (lt)
MA (1) MA52482B1 (lt)
MD (1) MD3788043T2 (lt)
MX (1) MX2020011489A (lt)
MY (1) MY205690A (lt)
NI (1) NI202000074A (lt)
PE (1) PE20210052A1 (lt)
PH (1) PH12020551779A1 (lt)
PL (1) PL3788043T3 (lt)
PT (1) PT3788043T (lt)
RS (1) RS66290B1 (lt)
SG (1) SG11202010459XA (lt)
SI (1) SI3788043T1 (lt)
TW (1) TWI839355B (lt)
UA (1) UA126834C2 (lt)
WO (1) WO2019212927A1 (lt)
ZA (1) ZA202006507B (lt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
US12331022B2 (en) * 2019-05-02 2025-06-17 Merck Sharp & Dohme Llc Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
AU2020321955A1 (en) 2019-07-30 2022-03-17 Eikonizo Therapapeutics, Inc. HDAC6 inhibitors and uses thereof
US12534458B2 (en) * 2019-11-05 2026-01-27 Merck Sharp & Dohme Llc Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors
EP4077276A1 (en) * 2019-12-19 2022-10-26 Curia Spain S.A.U. Process and intermediates for the preparation of upadacitinib
TW202345813A (zh) 2022-04-08 2023-12-01 美商艾科尼佐療法股份有限公司 㗁二唑ｈｄａｃ６抑制劑及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004000754A1 (es) 2003-04-11 2005-02-25 Janssen Pharmaceutica Nv Uso de compuestos derivados de 4-fenil-4-(1h-imidazol-2-il)piperidina, como agonistas delta-opioides no peptidicos, para preparar un medicamento util en prevenir o tratar trastornos del sistema nervioso central.
ES2460897T3 (es) 2007-10-04 2014-05-14 F. Hoffmann-La Roche Ag Derivados de ciclopropil aril amida y usos de los mismos
KR101925971B1 (ko) 2011-01-28 2018-12-06 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
EP2670731B1 (en) 2011-02-02 2016-05-25 Bionomics Limited Positive allosteric modulators of the alpha 7 nicotinic acetylcholine receptor and uses thereof.
HRP20180913T1 (hr) 2011-07-08 2018-07-27 H. Lundbeck A/S Pozitivni alosterni modulatori receptora nikotinskog acetilkolina
UA111746C2 (uk) 2011-07-08 2016-06-10 Х. Луннбек А/С Позитивні алостеричні модулятори нікотинового рецептора ацетилхоліну
WO2014006120A1 (en) 2012-07-06 2014-01-09 H. Lundbeck A/S New positive allosteric modulators of nicotinic acetylcholine receptor
BR112015001959A2 (pt) 2012-08-01 2017-07-04 Merck Sharp & Dohme composto, composição farmacêutica, métodos para melhorar os déficits cognitivos, para prevenir ou tratar déficits cognitivos distúrbios neurodegenerativos ou neuropsiquiátricos, para o tratamento ou prevenção de doenças inflamatórias e de dor neuropática, uso de um composto, e, processo para preparar um composto
MX2015004285A (es) 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Derivado de imidazol.
HK1216095A1 (zh) 2012-12-10 2016-10-14 H. Lundbeck A/S 烟碱乙酰胆碱受体的新的正向别构调节剂
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
CN110072864B (zh) 2015-12-24 2022-05-27 基因泰克公司 Tdo2抑制剂
UA120571C2 (uk) * 2016-03-22 2019-12-26 Мерк Шарп Енд Дохме Корп. Алостеричні модулятори нікотинових ацетилхолінових рецепторів

Also Published As

Publication number Publication date
GEP20227409B (en) 2022-09-12
EP3788043B1 (en) 2024-11-06
SG11202010459XA (en) 2020-11-27
MY205690A (en) 2024-11-06
FI3788043T3 (fi) 2025-01-15
ECSP20067907A (es) 2021-02-26
PE20210052A1 (es) 2021-01-08
EP3788043A1 (en) 2021-03-10
KR20210005697A (ko) 2021-01-14
TW202014419A (zh) 2020-04-16
US11332463B2 (en) 2022-05-17
DK3788043T3 (da) 2024-12-16
AU2019262917A1 (en) 2020-11-05
CL2021001795A1 (es) 2021-12-24
MX2020011489A (es) 2020-12-07
RS66290B1 (sr) 2025-01-31
PT3788043T (pt) 2024-12-03
MA52482B1 (fr) 2024-12-31
PL3788043T3 (pl) 2025-03-10
BR112020022088A8 (pt) 2023-02-07
TWI839355B (zh) 2024-04-21
CR20200509A (es) 2020-12-23
CO2020013462A2 (es) 2020-11-10
PH12020551779A1 (en) 2021-06-07
MA52482A (fr) 2021-03-10
GEAP202215499A (en) 2022-05-10
CN112119076A (zh) 2020-12-22
ZA202006507B (en) 2025-06-25
CL2020002820A1 (es) 2021-02-19
JP2021523102A (ja) 2021-09-02
AR115065A1 (es) 2020-11-25
WO2019212927A1 (en) 2019-11-07
EA202092608A1 (ru) 2021-03-02
AU2019262917B2 (en) 2021-12-23
JP7073533B2 (ja) 2022-05-23
CA3098583C (en) 2023-05-16
IL278154B2 (en) 2025-06-01
HUE070339T2 (hu) 2025-05-28
JOP20200272A1 (ar) 2020-11-01
CN112119076B (zh) 2025-01-10
HRP20241704T1 (hr) 2025-02-14
US20210070745A1 (en) 2021-03-11
UA126834C2 (uk) 2023-02-08
NZ768954A (en) 2025-06-27
IL278154B1 (en) 2025-02-01
KR102587811B1 (ko) 2023-10-11
IL278154A (en) 2020-11-30
MD3788043T2 (ro) 2025-03-31
BR112020022088A2 (pt) 2021-02-02
SI3788043T1 (sl) 2025-01-31
ES2995040T3 (en) 2025-02-05
NI202000074A (es) 2021-03-05
CA3098583A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
LT3788043T (lt) Nikotino acetilcholino receptorių alosteriniai spiropiperidino moduliatoriai
LT3433234T (lt) Nikotino acetilcholino receptorių alosteriniai moduliatoriai
MA50205A (fr) Formulation de nicotine
SI3743406T1 (sl) Modulatorji TMEM16A
HUE061297T2 (hu) Az integrált stressz-útvonal prodrug modulátorai
IL283967A (en) Modulators of hsd17b13 expression
IL268824A (en) Improved antigen binding receptor formats
UA37801S (uk) Пристрій для інтраназального введення ліків
PT3507289T (pt) Moduladores alostéricos positivos do recetor muscarínico m1
IL281492A (en) Modulators of pnpla3 expression
DK3452448T3 (da) Modulatorer af den integrerede stressvej
EP3905900C0 (en) LIQUID NICOTINE FORMULATION
DK3197868T3 (da) N-alkylaryl-5-oxyaryl-octahydro-cyclopenta[c]pyrrol-negative allosteriske modulatorer af nr2b
IL272580A (en) Spirocycle compounds and methods of making and using same
BR112017026561A2 (pt) moduladores alostéricos positivos do receptor muscarínico m2
IL266505B (en) Heterocyclic modulators of lipid synthesis
UA40089S (uk) Кальян
IL282813A (en) Antibody formulation
EP3758704A4 (en) IRF4 EXPRESSION MODULATORS
EP3962483A4 (en) ALLOSTERIC SPIROPIPERIDINE MODULATORS OF NICOTINE ACETYLCHOLINE RECEPTORS
EP3534888A4 (en) SUBSTITUTED BICYCLIC HETEROARYL-ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
MA51038A (fr) Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4
EP3493803A4 (en) GP130 MODULATORS
EP4404935A4 (en) ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS
EP4404934A4 (en) ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS